Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes
暂无分享,去创建一个
G. Mufti | P. Fenaux | E. Hellström-Lindberg | S. Gore | V. Santini | J. Seymour | N. Gattermann | G. Sanz | A. List | L. Silverman
[1] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[2] G. Garcia-Manero. Improving survival in myelodysplastic syndromes. , 2009, The Lancet. Oncology.
[3] F. Lyko,et al. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.
[4] G. Mufti,et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission , 2008 .
[5] B. Zhivotovsky,et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. , 2008, Experimental hematology.
[6] A. Barrett,et al. Allogeneic stem cell transplantation for myelodysplastic syndrome. , 2008, Seminars in hematology.
[7] R. Larson,et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Grever,et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.
[9] M. Voso,et al. Profile of azacitidine , 2005 .
[10] G. Marcucci,et al. Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes , 2005, Journal of clinical pharmacology.
[11] V. Najfeld,et al. The Modulating Effect of Azacitidine (Aza C) on the Cytogenetically Tracked MDS Clone Impact Survival. , 2004 .
[12] J. Herman,et al. Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.
[13] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Holland,et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Issa,et al. Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.
[16] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[17] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[18] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[19] J. Christman,et al. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.
[20] Peter A. Jones,et al. Multiple new phenotypes induced in 10T 1 2 and 3T3 cells treated with 5-azacytidine , 1979, Cell.
[21] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .